

Avastin[®], Lucentis[®] and Eylea[®] Protocol

1. CMS allows Medicare Advantage plans to use Step Therapy for Part B drugs.
2. Avastin[®] (Bevacizumab) is the preferred Anti-VEGF drug of choice for all Premier contracted Health Plans.
 - a. Premier requires members with diagnoses of Age Related Macular Degeneration (AMD) and Retinal Vein Occlusions (RVO), to start treatment with Avastin[®] before trying Eylea[®] or Lucentis[®].
 - b. Premier requires members with Diabetic Macular Edema (DME) with **BCVA/PH vision 20/40 or better**, to start treatment with Avastin[®] before trying Eylea[®] or Lucentis[®].
 - c. Members with Diabetic Macular Edema (DME) with **BCVA/PH vision 20/50 or worse**, may start treatment with Eylea[®] or Lucentis[®].
 - d. Eylea[®] and Lucentis[®], may be considered appropriate for AMD, RVO, and DME, when a member has had prior therapy, contraindication or intolerance to Avastin[®].
3. For members with a previous history of Lucentis[®] and/or Eylea[®] treatments within the last 365 days, should be advised of the cost difference between Avastin[®] and Lucentis[®] and/or Eylea[®] and advised that the drugs work similarly. If the member has not been treated within 365 days, the member is to restart step therapy using Avastin[®].
4. Premier recognizes that Avastin[®] is being used in an “off label” manner, while Lucentis[®] and Eylea[®] are FDA approved.
5. All Premier contracted health plans follow CMS guidelines regarding the additional uses of Avastin[®], Lucentis[®] and Eylea[®] to treat eye conditions other than macular degeneration.

6. Avastin® to be the drug of choice for all members with a history of Avastin® treatments, documented in the medical record.